Literature DB >> 21902822

Hepatitis C virus genotypes in Pakistan: a systemic review.

Sobia Attaullah1, Sanaullah Khan, Ijaz Ali.   

Abstract

BACKGROUND AND AIM: Phylogenetic analysis has led to the classification of hepatitis C virus (HCV) into 1-6 major genotypes. HCV genotypes have different biological properties, clinical outcome and response to antiviral treatment and provide important clues for studying the epidemiology, transmission and pathogenesis. This article deepens the current molecular information about the geographical distribution of HCV genotypes and subgenotypes in population of four provinces of Pakistan. 34 published papers (1996-2011) related to prevalence of HCV genotypes/serotypes and subgenotypes in Pakistan were searched. RESULT: HCV genotype/s distribution from all 34 studies was observed in 28,400 HCV infected individuals in the following pattern: 1,999 (7.03%) cases of genotype 1; 1,085 (3.81%) cases of genotype 2; 22,429 (78.96%) cases of genotype 3; 453 (1.59%) cases of genotype 4; 29 (0.10%) cases of genotype 5; 37 (0.13%) cases of genotype 6; 1,429 (5.03%) cases of mixed genotypes, and 939 (3.30%) cases of untypeable genotypes. Overall, genotype 3a was the predominant genotype with a rate of 55.10%, followed by genotype 1a, 3b and mixed genotype with a rate of 10.25%, 8.20%, and 5.08%, respectively; and genotypes 4, 5 and 6 were rare. Genotype 3 occurred predominately in all the provinces of Pakistan. Second more frequently genotype was genotype 1 in Punjab province and untypeable genotypes in Sindh, Khyber Pakhtunkhwa and Balochistan provinces.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21902822      PMCID: PMC3178528          DOI: 10.1186/1743-422X-8-433

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


Background

Hepatitis C virus (HCV) infection, the sole member of the genus Hepacivirus, in the family Flaviviridae [1], is a global public health problem [1-3] and is accountable for the second most common cause of viral hepatitis [4]. Pakistani HCV serofrequency figures are significantly higher (4.7%, varying from 0.4%-33.7%) when compared to the corresponding populations in surrounding countries like India (0.66%), Nepal (1.0), Myanmar (2.5%), Iran (0.87%) [5], China (1%) [6] and Afghanistan (1.1%) [7]. HCV has been recognized to be both hepatotropic and lymphotropic virus [8]. The complete HCV genome was determined by Choo et al in 1991 and the consensual international classification was made in 1994 [6]. HCV genome is comprised of linear single stranded RNA molecule of positive polarity of ~9.6 kb [1]. The RNA encodes a large polyprotein of about 3,000 amino acids in a single continuous open reading frame (ORF) which is flanked at the 5' and 3' ends by nontranslated regions (5' UTR) [1,2,9]. The ORF comprised of 3 structural genes (C, E1, E2) and 4 nonstructural genes (NS2, NS3, NS4 and NS5) [2,9]. Mutation rate are different in different region of HCV genome. High rate of mutation occur in two region of Envelop E2 glycoprotein, designated hyper variable region 1 and 2 [10]. Of the genome, 5'UTR, the most highly conserved region and thus has been used is most laboratories to develop sensitive detection assays for HCV RNA [2,9]. RNA exhibits a significant genetic, heterogeneity with nucleotide substitution rate of 1.44 × 10-3 and 1.92 × 10-3 per site per year [11]. HCV isolates show four levels of genetic variability: types (65.7% - 68.9% nucleotide sequence identities of full length sequences), subtypes (76.9% - 80.1% nucleotide sequence identities of full length sequences), isolates, and quasispecies (90.8%- 99% nucleotide sequence identities of full length sequences) [6]. Epidemiologically and clinically HCV is classified into 11 genotypes and more than 100 subtypes designated as a, b, c. etc. [1,6,12]. It has been regarded that genotypes 7 through 11 should be consider as variants of the same group and classified as a single genotype, type 6 [13,14]. Genetic heterogeneity is an outstanding feature of HCV and this may have important implications in diagnosis, pathogenesis, treatment, and vaccine development. The determination of HCV genotypes, subtypes and isolates has been helpful in understanding the evolution and the epidemiology of the HCV, and is an important factor in the pretreatment evaluation of patients [8,15,16]. The HCV genotypes show a distinctive geographical distribution [6,9,15]. The global epidemiology of the HCV genotypes is shown in Table 1[13,14].
Table 1

Geographic Distribution of HCV Genotypes Worldwide

HCV GenotypesGeographical distribution
1United States, Europe, Japan

2Northern Italy, North America, Europe, and Japan

3India, Europe, United States

4North Africa and the Middle East

5South Africa

6Hong Kong

7,8,9Vietnam

10,11Indonesia
Geographic Distribution of HCV Genotypes Worldwide In Pakistan, few studies have been conducted in order to figure out the distribution of various HCV genotypes. This study initiated to find out the molecular epidemiology of various HCV genotypes and subtypes present across the country in all four provinces of Pakistan.

Literature search

Literature was searched and reviewed in 2011 to summarize scientific reports on distribution, prevalence and epidemiology of HCV genotypes in Pakistan. Articles indexed in the PubMed database and google scholar. Papers published during years 1996 to 2011 were searched by using the following key words: HCV, hepatitis C virus genotypes, epidemiology, prevalence, Pakistan. A total of 34 original articles on HCV genotype in Pakistan were found; they covered all four provinces. Altogether 28,400 HCV affected individuals were reported in these articles. In this study, 3,887 cases of positive HCV individuals were investigated from Punjab, 2,868 cases from Sindh, 1,200 cases from Khyber Pakhtunkhwa (formerly NWFP) and 152 individuals was available from Balochistan, while 20,417 individuals were investigated from different parts of Pakistan (Table 2).
Table 2

Distribution of HCV Genotypes in 34 studies from Pakistan

Ref. NoHCV Genotype frequency (%)

123456untypeablemixed
[17]1(6.66)-13(80)---1(13.33)-

[18]4(6.66)1(2.22)a = 39(87)1(2.22)----

[19]18(6.4)3(1.07)a = 171(61.5)-2(0.9)63(22.6)--

[20]31(10)6(1.96)a = 198(64.7)1(0.32)7(2.28)51(16.6)6(1.96)

[21]20(5.6)-241(82.5)15(4.2)--64(18)-

[22]--314(100)-----

[23]--a = 8(89),b = 1(11)-----

[24]57(7.9)8(12)636(87.8)36(5)-6(0.8)--

[15]a = 10(10.2)a = 3(3.1)a = 62(63.3), b = 8(8.2)---11(11.2)4(4.08)

[16]b = 21(13.5)-a = 80(51.6), b = 43(27.7)---5(3.22)6(3.87)

[25]10(31)-18(56)----4(13)

[26]8(9.5)2(2.4)68(81)---6(7)

[27]80(4.84)154(9.33)1220(73.85)41(2.84)--106(6.42)51(3.09)

[28]a = 280(8.3), b = 101(3.0), c = 5(0.15),a = 252(7.5), c = 3(0.09)a = 1664(49.05), b = 592(17.66), c = 25(0.15)50(1.49)a = 6(0.18)4(0.12)201(5.99)161(4.8)

[29]a = 10(2.9), b = 5(0.15)-a = 242(70.3), b = 19(5.52)-3(0.87)-52(15.11)9(2.61)

[30]a = 2(7.14)-a = 14(50), b = 3(10.72)---9(32.14)-

[31]b = 10(4.81)-a = 107(51.44), b = 33(15.87)---8(3.84)50(24.04)

[32]b = 10(4.5)-74(33.7)---8(3.6)19(8.7)

[33]a = 4(2)-a = 115(57.5), b = 6(3)---34(17)41(20.5)

[2]a = 1(1.07)-a = 81(87.09)---9(9.67)2(2.14)

[3]--a = 8(38)---11(52.4)2(9.6)

[34]a = 8(9.63), b = 2(2.4)-a = 34(40.96), b = 13(15.66)---2(2.4)24(28.91)

[35]a = 2(1.5),b = 1(0.8),c = 2(1.5)a = 1(0.8)a = 105(81.4), b = 12(9.3), k = 3(2.3)a = 3(3.2)----

[1]a = 12(10),b = 6(5),c = 1(0.8)a = 8(6.7)a = 58(48.7), b = 24(20)---3(2.5)7(5.9)

[36]a = 678(3.3), b = 170(0.83),c = 49(0.24)a = 431(2.1), b = 48(0.23), c = 3(0.01)a = 12537(74.2), b = 18834(10.9), c = 50(0.24)101(0.49a = 13(0.07)a = 12(0.06)-965(4.7

[13]a = 9(2.17),b = 3(0.722)-a = 234(56.38),b = 25(6.02)---116(27.95)28(6.74)

[37]-a = 1(2.1)a = 28(65.1), b = 4(9.3)-a = 5(11.6)a = 5(11.6)--

[6]a = 322(23.6)-a = 763(55.9), b = 43(3.2)a = 170(12.5), b = 16(1.17)--34(2.5)16(1.2)

[38]a = 1(4),b = 2(8)a = 4(16),b = 1(4)a = 11(44),b = 3(12)---3(12)-

[4]a = 3(1.5), b = 5(2.5)a = 78(39), b = 2(1)a = 62(31), b = 16(8)---34(17)-

[39]a = 5(7.9)a = 22(34.9)a = 18(28.6)9(14.3)--9(14.3)-

[14]a = 10(5.4)a = 15(8.1)a = 63(34.1), b = 13(7)---70(37.8)14(7.6)

[40]a = 1(4.34)-a = 17(73.91), b = 3(13.04)---1(4.34)1(4.34)

[41]a = 3(13)-a = 15(65),b = 4(17)---1(4)-
Distribution of HCV Genotypes in 34 studies from Pakistan

Discussion and Conclusion

HCV has come to the top of virus-induced liver diseases in many parts of the world and has gained endemic proportions in our population but there is no national data collection system for evaluation of genotypes of HCV infection. The data on geographic distribution of genotypes of HCV is among largest of its kind from Pakistan. This is perhaps the first study done in area of geographic distribution of genotypes of HCV in all four provinces of Pakistan. Pakistan is situated in the western part of the Indian subcontinent, with Afghanistan and Iran on the west, India on the east, and the Arabian Sea on the south. This geographical situation, mass immigration and illegal drug traffic from Afghanistan, absence of good preventive measures in the past e.g. extensive reuse of non-sterilized syringes, fragile health structure, unscreened blood transfusion, use of contaminated razor by barber, general poverty and poor education have all affected epidemiology of HCV in our country. Pakistan consists of four provinces; Balochistan is geographically largest of four provinces but has smallest population; Punjab is second largest province and has largest population, Sindh is third largest province geographically and KPK is geographically the smallest of four provinces, which is bordered on to the west by Afghanistan. The immigration of populations from countries of high endemicity of the infection seems to contribute significantly to the rapid modification of epidemiological data, especially in areas bearing the high burden of immigrants. Genotype 1 was accounted 7.03% of the cases and subtype 1a predominated with a rate of 4.82%. Genotype 2 had frequency of 3.81% and most frequent subtype was 2a (2.89%). Genotype 3 alone contributed to at least 78.96% of all isolates and most frequent subtype was 3a (58.01%), followed by 3b (9.76%). Genotype 4, 5 and 6 were rare with the rate of 1.59%, 0.10% and 0.13, respectively. The rates for mixed genotype, and untypeable genotypes were 5.03%, and 3.30%, respectively (Table 3, Figure 1 and 2 showed distribution of genotypes/subtypes in Pakistan). HCV genotypes of mixed infection have been investigated in only 118 (8.25%) individuals and mixed subtypes in 157 (10.98%) individuals. Mixed infection 1&3 was found with the rate of 0.35%, 1&4 (0.003%), 3&6 (0.021%), 2&3 (0.017%), 3&5 (0.007%), 3&4 (0.003%), 1&5 (0.007%) and 2&4&6 (0.007%). The most frequent mixed subtype was 3a&3b (0.387%), followed by 1a&3a (0.06%), 1b&3a (0.05), 1a&3b (0.024%), 2b&3a (0.014%) and 2a&3a (0.010%).
Table 3

HCV Genotype/subtypes Distribution in Pakistan

GenotypeFrequencyPercentage
1 (all subtypes)19997.038

 1(Undefined subtypes)2370.834

 1a13694.82

 1b3361.183

 1c570.2

2 (all subtypes)10853.818

 2 (Undefined subtypes)1800.633

 2a8212.89

 2b780.274

 2c60.021

3 (all subtypes)2242978.964

 3 (Undefined subtypes)310410.92

 3a1647558.01

 3b27729.76

 3c750.264

 3k30.01

4 (all subtypes)4531.594

 4 (Undefined subtypes)2640.929

 4a1730.609

 4b160.056

5 (all subtypes)290.101

 5 (Undefined subtypes)50.017

 5a240.084

6(all subtypes)370.13

 6 (Undefined subtypes)250.088

 6120.042

Undefined subtypes9393.306

Mixed14295.031

Total28400100
Figure 1

Distribution of HCV Genotypes in Pakistan.

Figure 2

Distribution of HCV Genotypes in all provinces of Pakistan.

HCV Genotype/subtypes Distribution in Pakistan Distribution of HCV Genotypes in Pakistan. Distribution of HCV Genotypes in all provinces of Pakistan. This study showed that HCV infections in hepatitis patients are attributed predominantly to viral genotype 3 in Pakistan with the rate of 68.94% in Punjab, 76.88% in Sindh, 58% in KPK and 60.71% in Balochistan. In addition, there was a relatively high prevalence of genotype 1 (12.14%) in Punjab while untypeable infection represented the second more frequent genotype among the studied population in Sindh (8.33%), KPK (20.16%) and Balochistan (32.14%). Statistically no difference was found in HCV genotypes in terms of age and sex of the patients, also confirmed by other studies [14,42,43] but in contrast to reports from developed countries like USA and Southeast Asia, where lifestyles among young adults seem to have influenced the molecular epidemiology of HCV especially by their young drug addicts [42]. With reference to this countrywide information this study suggested that HCV 3 was the leading genotype in Pakistan. Other major types were genotype 1 and mixed genotype. A high prevalence of variants of genotype 3 alone to be over 79.43% in Pakistan overall- alone or in combination with another genotype (78.96% had genotype alone, and a further 157/157 had this genotype mixed with another genotype). High prevalence of HCV genotype 3 in Pakistan is a good hope for cure as well as control of HCV infection [6,15]. Genotype 3 requires shorter duration of treatment as compared with genotype 1, with its associated reduced cost and side effects [33]. The predominance of HCV genotype 3 in our population confirmed the predominance of HCV genotype 3 in the surrounding countries including India [2,15,16], Iran [44], Bangladesh [14,15] and China [2]. Each genotype has few subtypes in Pakistan, three for Genotype 1, three for genotype 2, four for genotype 3, two for genotype 4, one for genotype 5 and one for genotype 6. This showed reduced diversity of subtypes in Pakistan. It would therefore appear from different studies conducted in different parts that substantial regional differences do exist in our country. Genotype 1 is the second highest genotype in the country. Balochistan shares a long border with Iran in the west where genotypes 1a and 3a are most prevalent [3,45]. High prevalence of genotype 3a and 1b has been reported from China [2]. It is quite possible that genotype 1 may have entered into Pakistan from these countries through local persons who cross borders for job and trade. Shifts in HCV genotype distribution needs to be paid more attention. This raises an alarming signal on the major steps to be taken to reduce such infection as genotype 1a and 4a are associated with severe cirrhosis. A proportion of patients will have their genotype reported untypeable (3.306%). Presence of untypeable samples in indicated that some novel genotypes are present in Pakistan. Our next goal should be to find out the sequencing of these samples, which will be very useful in prescribing the therapy for patients [1]. For being able to identify untypeable genotypes, phylogenetic analysis of extensive genome sequences is required and continuous efforts are required toward a better characterization of this variant. Most of the studies were not able to separate different kinds of patients among the untypeable genotype group because of the retrospective nature of their studies. Other studies were unable to sequence the untypeable samples due to lack of sequencing facility.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SA and SK designed, analyzed and draft the manuscript. IA critically studied the manuscript. All authors read and approved the final manuscript.
  28 in total

1.  HCV serotypes in Karachi: a Liaquat National Hospital experience.

Authors:  N Ansari; A Ahmed; J Esmail; S A Mujeeb
Journal:  J Pak Med Assoc       Date:  2002-05       Impact factor: 0.781

2.  Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience.

Authors:  Muhammad Idrees; Amreek Lal; Fayyaz Ahmed Malik; Abrar Hussain; Irshad ur Rehman; Haji Akbar; Sadia Butt; Muhammad Ali; Liaqat Ali; Fayyaz Ahmed Malik
Journal:  Infect Genet Evol       Date:  2010-12-22       Impact factor: 3.342

3.  The occurrence of hepatitis B and C viruses in Pakistani patients with chronic liver disease and hepatocellular carcinoma.

Authors:  C Y Tong; R Khan; N J Beeching; W U Tariq; C A Hart; N Ahmad; I A Malik
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

Review 4.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Authors:  Peter Simmonds; Jens Bukh; Christophe Combet; Gilbert Deléage; Nobuyuki Enomoto; Stephen Feinstone; Phillippe Halfon; Geneviève Inchauspé; Carla Kuiken; Geert Maertens; Masashi Mizokami; Donald G Murphy; Hiroaki Okamoto; Jean-Michel Pawlotsky; François Penin; Erwin Sablon; Tadasu Shin-I; Lieven J Stuyver; Heinz-Jürgen Thiel; Sergei Viazov; Amy J Weiner; Anders Widell
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

5.  Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan.

Authors:  Irshad-Ur Rehman; Muhammad Idrees; Muhammad Ali; Liaqat Ali; Sadia Butt; Abrar Hussain; Haji Akbar; Samia Afzal
Journal:  Genet Vaccines Ther       Date:  2011-01-06

6.  Prevalence of hepatitis C virus (HCV) genotypes among positive UAE patients.

Authors:  Mubarak S Alfaresi
Journal:  Mol Biol Rep       Date:  2010-11-20       Impact factor: 2.316

7.  Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan.

Authors:  Abdul Rauf; Muhammad Shahid Nadeem; Akbar Ali; Muhammad Iqbal; Muhammad Mustafa; Muhammad Muzammal Latif; Muhammad Zahid Latif; Nisar Ahmed; Abdul Rauf Shakoori
Journal:  Eur J Public Health       Date:  2010-07-03       Impact factor: 3.367

8.  Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience.

Authors:  Muhammad Idrees; Shazia Rafique; Irshadur Rehman; Haji Akbar; Muhammad-Zubair Yousaf; Sadia Butt; Zunaira Awan; Sobia Manzoor; Madiha Akram; Mahwish Aftab; Bushra Khubaib; Sheikh Riazuddin
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 9.  Epidemiology of hepatitis C virus infection in Pakistan.

Authors:  Nadeem Sajjad Raja; Khalid Abbas Janjua
Journal:  J Microbiol Immunol Infect       Date:  2008-02       Impact factor: 4.399

10.  Seroprevalence of hepatitis B and C genotypes among young apparently healthy females of karachi-pakistan.

Authors:  St Hakim; Su Kazmi; O Bagasra
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

View more
  34 in total

1.  Hepatitis C virus transmission cluster among injection drug users in Pakistan.

Authors:  Kashif Iqbal Sahibzada; Lilia Ganova-Raeva; Zoya Dimitrova; Sumathi Ramachandran; Yulin Lin; Garrett Longmire; Leonard Arthur; Guo-Liang Xia; Yury Khudyakov; Idrees Khan; Saima Sadaf
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

2.  Molecular epidemiology of Hepatitis B virus, Hepatitis C virus, and Hepatitis D virus in general population of Afghanistan.

Authors:  Abbas Ali Husseini; Khwaja Mir Islam Saeed; Esra Yurdcu; A Mithat Bozdayı
Journal:  Turk J Gastroenterol       Date:  2020-09       Impact factor: 1.852

3.  Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection.

Authors:  A H Hashmi; N Ahmad; S Riaz; L Ali; S Siddiqi; K M Khan; A R Shakoori; A Mansoor
Journal:  Genes Immun       Date:  2014-06-05       Impact factor: 2.676

4.  Identification of rare hepatitis C virus genotype 5a among Indian population.

Authors:  Rahamathulla Syed; Vishnu Priya Satti; Aejaz Habeeb; M N Khaja
Journal:  Virus Genes       Date:  2013-04-11       Impact factor: 2.332

5.  A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12

6.  Selection of epitope-based vaccine targets of HCV genotype 1 of Asian origin: a systematic in silico approach.

Authors:  Abida Shehzadi; Shahid Ur Rehman; Tayyab Husnain
Journal:  Bioinformation       Date:  2012-10-13

Review 7.  Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries.

Authors:  Sina Aziz
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

8.  Distribution and predominance of genotype 3 in hepatitis C virus carriers in the province of kahramanmaras, Turkey.

Authors:  Ahmet Caliskan; Ozlem Kirisci; Esra Ozkaya; Sevinc Ozden; Seray Tumer; Serkan Caglar; Selma Ates Guler; Hande Senol
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660

9.  Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India.

Authors:  Varun Mehta; Ramit Mahajan; Vandana Midha; Vikram Narang; Kirandeep Kaur; Arshdeep Singh; Anand Malhotra; Aslam Parvez; Ajit Sood
Journal:  J Clin Exp Hepatol       Date:  2017-06-19

10.  A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients.

Authors:  Sadia Qamar Arain; Farah Naz Talpur; Naseem Aslam Channa
Journal:  Lipids Health Dis       Date:  2015-09-24       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.